Semax: Dosage & Administration

Semax is approved in Russia by the Ministry of Health (since 1996) under the brand name "Semax" in two strengths: 0.1% nasal spray for cognitive disorders and 1% nasal spray for ischemic stroke, transient ischemic attack (TIA), and serious neurological conditions. Russian-approved dosing is the most rigorously documented Semax protocol — Western research-peptide community protocols derive from these.^[1]

FDA update: Semax-related bulk drug substances (Semax free base and Semax acetate) are scheduled for discussion at the July 23–24, 2026 FDA Pharmacy Compounding Advisory Committee meeting (docket FDA-2025-N-6895). If the committee recommends and FDA finalizes inclusion on the 503A bulks list, Semax could become legally compoundable by licensed US pharmacies with a valid prescription in late 2026 / Q1 2027. Until then, US use is research-only.

Application	Formulation	Total Daily Dose	Frequency	Course Length
Cognitive enhancement (healthy / mild impairment)	0.1% nasal spray	200–600 mcg	2–3 drops per nostril, 2–3× daily	10–14 days
Cognitive impairment / mild dementia (Russian protocol)	0.1% nasal spray	600–900 mcg	3 drops per nostril, 3× daily	14 days; can repeat after rest
Acute ischemic stroke (Russian protocol)	1% nasal spray	9–18 mg	3 drops per nostril, 3–4× daily	10–14 days hospital protocol
TIA / mild stroke recovery	1% nasal spray	3–6 mg	2–3 drops per nostril, 3× daily	10–14 days
Subcutaneous (research)	Reconstituted	200–1,000 mcg	Once or twice daily	10–14 days

One drop of the 0.1% spray delivers approximately 50 mcg; one drop of the 1% spray delivers approximately 500 mcg. The wide range across applications reflects Semax's well-characterized dose-response — lower doses for cognitive support, higher doses for active neurological pathology.^[2]

Intranasal is the preferred route. The olfactory pathway provides direct nose-to-brain delivery, bypassing the blood-brain barrier and producing rapid CNS effects within minutes.

Technique

• Tilt head back slightly (not all the way back) before applying drops.
• Apply drops to the inside upper portion of the nostril — not into the back of the throat.
• Stay still for 30 seconds after dosing to allow absorption.
• Alternate nostrils across doses to distribute mucosal exposure.
• Do not blow your nose for at least 15 minutes after dosing.
• Saline rinse before dosing (if you have congestion) improves absorption — wait 15 minutes after rinsing.

Effects on attention, working memory, and mood typically appear within 30–60 minutes of intranasal dosing. Peak plasma concentration occurs within 4 minutes; CNS effects persist for several hours.^[3]

Semax is mildly activating. Standard timing guidance:

• Morning and early afternoon dosing only — last dose before 14:00.
• Avoid evening doses — Semax can interfere with sleep onset.
• Take consistently at the same times for steady-state plasma levels across the course.
• Independent of meals — food does not significantly affect intranasal Semax absorption.

Cycle length

• Standard course: 10–14 days, matching Russian clinical protocols.
• Rest periods: 7–14 days off between courses is the typical pattern. Russian protocols sometimes repeat 2–3 courses with rest in between for chronic cognitive disorders.
• Avoid continuous indefinite use — long-term continuous-dose safety in healthy adults is poorly characterized.

Subcutaneous injection is less commonly used than intranasal because:

• Intranasal achieves direct CNS delivery; SC produces only systemic distribution that crosses the BBB less efficiently.
• SC requires reconstitution and injection vs. simple drops.
• Russian approved protocols use intranasal exclusively.

If using SC: typical doses are 200–1,000 mcg once or twice daily for 10–14 days. Reconstitute with bacteriostatic water — use the peptide calculator for volumes. See the reconstitution guide for technique.

Several modified Semax derivatives have been developed by Russian researchers to improve stability or duration of action:

• NA-Semax (N-acetyl Semax): the N-terminus is acetylated to resist enzymatic degradation. Reportedly longer-acting than standard Semax.
• NA-Semax Amidate (N-acetyl Semax amide): both N-terminus acetylated AND C-terminus amidated. Further enhanced stability.
• Selank / Semax combinations: not a Semax variant per se, but the two heptapeptides are sometimes co-administered for combined anxiolytic + cognitive effects. See Selank.

These variants lack the formal clinical trial backing of standard Semax. Doses are typically reduced (50–70% of standard Semax dose) due to reportedly improved bioavailability, but this is based on research-community convention rather than published pharmacokinetic data.

• Russian-manufactured nasal spray: store at 2–8°C (refrigerator). Per label, do not freeze. Use within product expiration date.
• Lyophilized powder (research vial): -20°C long-term; 2–8°C short-term.
• Reconstituted solution: refrigerate at 2–8°C, use within 28 days.
• Protect from light.

For broader storage rules, see the peptide storage guide.